Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21359154 | 0.72 | HRH3 (0.49) | HRH3HRH4SMN1; SMN2L3MBTL1ACHE | |
| SCHEMBL28044074 | 0.71 | EPHX1 (0.47) | HRH3HRH4SMN1; SMN2L3MBTL1ACHE | |
| SCHEMBL15961737 | 0.70 | HRH3 (0.47) | HRH3KMT2AHRH4POLBLMNA | |
| SCHEMBL23607697 | 0.70 | HRH3 (0.52) | HRH3HRH4SMN1; SMN2L3MBTL1 | |
| SCHEMBL18094706 | 0.70 | THRB (0.49) | HRH3HRH4THRBALDH1A1ACHE | |
| SCHEMBL24798057 | 0.70 | ITGB3 (0.42) | KMT2ASMN1; SMN2 | |
| SCHEMBL18094736 | 0.70 | TSHR (0.50) | HRH3HRH4THRBALDH1A1 | |
| SCHEMBL22338188 | 0.70 | MEN1 (0.43) | KMT2ALMNASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL25779990 | 0.70 | MEN1 (0.43) | KMT2ALMNASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL21377157 | 0.69 | POLB (0.51) | KMT2APOLBLMNATHRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8137695-B2 | Transferring interfering RNA sequences into cells via conjugation with physiologically labile bond associated with polyamine and/or polyvinyl ether | Arrowhead Madison Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138383-B2 | For cellular delivery; heterogeneity polymer containing cationic groups and hydrophobic groups | Arrowhead Madison Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8017109-B2 | Cellular deivery, random polyacrylate with multiple hydrophobic monomer | ROCHE MADISON INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8008355-B2 | Delivering nucleic acids to cells; copolymer containing amine monomer and hydrophobic segments | ROCHE MADISON INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7985406-B2 | For cellular delivery; heteropolymer containing amine containing monomer and hydrophobic monomers | ROCHE MADISON INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20090048410-A1 | Membrane Active Heteropolymers | Arrowhead Pharmaceuticals, Inc. | 2009-02-19 | — | — | US | disclosed |
| US-20090023890-A1 | Membrane Active Heteropolymers | Arrowhead Pharmaceuticals, Inc. | 2009-01-22 | — | — | US | disclosed |
| US-20080287630-A1 | Endosomolytic Poly(Acrylate) Polymers | Arrowhead Pharmaceuticals, Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080287628-A1 | Endosomolytic Poly(Vinyl Ether) Polymers | Arrowhead Madison Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080281041-A1 | Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080269450-A1 | Endosomolytic Poly-Beta-Aminoester Polymers | ROCHE MADISON INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080152661-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | Arrowhead Pharmaceuticals, Inc. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152661-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | PHAX, PCBP1, NCL | HRH3 2867/4885KMT2A 4125/4885HRH4 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.